💊 Arzneimittel A-Z 🧬 Targets 🛠 Werkzeuge 📚 Leitfäden
Alle Arzneimittel Arzneimittelklassen Therapeutische Bereiche Nebenwirkungen
Leitfäden Glossar Zeitleiste
Vergleiche Arzneimittelreisen Arzneimittel-Wirkstoffgruppen
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Esomeprazole

CHEMBL1201320 Phase 4 Zugelassen Small molecule
Half-Life
1-1.5 hours
Bioavailability
—
Protein Binding
—
Molecular Weight
345.4 g/mol
LogP
2.2
Phase
4

This proton pump inhibitor reduces stomach acid production by blocking the enzyme in the stomach lining that secretes acid. It is used to treat acid reflux, stomach ulcers, and conditions caused by too much stomach acid.

Molekularmasse

345,4170 g/mol

LogP

2,20

TPSA

96,30 Ų

Lipinski-Regel der Fünf

Bestanden

Therapeutische Bereiche

Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Cardiovascular Disease Pain Management Non-Small Cell Lung Cancer Rheumatoid Arthritis Osteoporosis Asthma Chronic Obstructive Pulmonary Disease Immunology Epilepsy Schizophrenia Generalized Anxiety Disorder Gastroesophageal Reflux Disease Psoriasis Multiple Sclerosis Non-Alcoholic Fatty Liver Disease Deep Vein Thrombosis / Pulmonary Embolism Obesity Lymphoma Type 2 Diabetes Hypertension Breast Cancer Chronic Pain Prostate Cancer Colorectal Cancer

Arzneimittelklassen

A — A - Alimentary Tract and Metabolism

Wirkmechanismus

S-isomer of omeprazole; proton pump inhibitor irreversibly blocking gastric H+/K+-ATPase.

Pharmacokinetics (PK)

Half-Life 1-1.5 hours

Pharmacodynamics (PD)

Mechanismus

S-isomer of omeprazole; proton pump inhibitor irreversibly blocking gastric H+/K+-ATPase.

2D-Struktur

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
COc1ccc2[nH]c([S@@+]([O-])Cc3ncc(C)c(OC)c3C)nc2c1

                

                

                
                

                    
InChI

                    
InChI=1S/C17H19N3O3S/c1-10-8-18-15(11(2)16(10)23-4)9-24(21)17-19-13-6-5-12(22-3)7-14(13)20-17/h5-8H,9H2,1-4H3,(H,19,20)/t24-/m0/s1

                

                

                

                    
                    

                        
Molecular Formula

                        
C17H19N3O3S

                    

                    
                    

                        
HBD / HBA

                        
1 / 6

                    

                    
                    

                        
Rotierbare Bindungen

                        
5

                    

                    
                    
                    

                        
Schwere Atome

                        
24

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
Häufig gestellte Fragen

                

                    
                    

                        
                        

                            
This proton pump inhibitor reduces stomach acid production by blocking the enzyme in the stomach lining that secretes acid. It is used to treat acid reflux, stomach ulcers, and conditions caused by too much stomach acid.

                        

                    

                    

                    

                    
                    

                        
                        

                            
S-isomer of omeprazole; proton pump inhibitor irreversibly blocking gastric H+/K+-ATPase.

                        

                    

                    

                    
                    

                        
                        

                            
Key pharmacokinetic parameters for Esomeprazole: Half-life: 1-1.5 hours.

                        

                    

                    

                    

                        
                        

                            
Yes, Esomeprazole is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            
            

                
Related Drugs


                
                

                    
Same Drug Class

                    

                        
                        
                            Metformin
                            Small molecule
                        
                        
                        
                            Omeprazole
                            Small molecule
                        
                        
                        
                            Pantoprazole
                            Small molecule
                        
                        
                        
                            Lansoprazole
                            Small molecule
                        
                        
                    

                

                

                
            

            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL1201320.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 9568614.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.




        


        
        
    


    



    
Medizinischer Haftungsausschluss

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.